Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against other stocks that Jim Cramer discusses in latest lightning round. On Thursday, Jim Cramer ...

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego ...

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN stock.

SHANGHAI, March 4 (Reuters) - China announced a ban on Tuesday on imports of genetic sequencers from U.S. medical equipment maker Illumina (ILMN.O), opens new tab ...

Illumina, Inc. (NASDAQ ... We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything. This isn’t a maybe – it’s an inevitability.

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers explore cellular behavior mapped across complex tissues. The announcement ...

Illumina and next-gen sequencing (NGS) are synonymous. But to anyone paying attention, the company’s recent emphasis on multiomics has been hard to miss. Indeed, the company has launched both ...

Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity.